Suppr超能文献

单胺氧化酶B抑制剂司来吉兰可降低人脑中F-THK5351的摄取。

Monoamine oxidase B inhibitor, selegiline, reduces F-THK5351 uptake in the human brain.

作者信息

Ng Kok Pin, Pascoal Tharick A, Mathotaarachchi Sulantha, Therriault Joseph, Kang Min Su, Shin Monica, Guiot Marie-Christine, Guo Qi, Harada Ryuichi, Comley Robert A, Massarweh Gassan, Soucy Jean-Paul, Okamura Nobuyuki, Gauthier Serge, Rosa-Neto Pedro

机构信息

Translational Neuroimaging Laboratory, The McGill University Research Centre for Studies in Aging, 6825 LaSalle Boulevard, Verdun, Québec, H4H 1R3, Canada.

Department of Neurology, National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore, 308433, Singapore.

出版信息

Alzheimers Res Ther. 2017 Mar 31;9(1):25. doi: 10.1186/s13195-017-0253-y.

Abstract

BACKGROUND

F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). However, high levels of F-THK5351 retention in brain regions thought to contain negligible concentrations of PHF raise questions about the interpretation of the positron emission tomography (PET) signals, particularly given previously described interactions between quinolone derivatives and monoamine oxidase B (MAO-B). Here, we tested the effects of MAO-B inhibition on F-THK5351 brain uptake using PET and autoradiography.

METHODS

Eight participants (five mild cognitive impairment, two Alzheimer's disease, and one progressive supranuclear palsy) had baseline F-AZD4694 and F-THK5351 scans in order to quantify brain amyloid and PHF load, respectively. A second F-THK5351 scan was conducted 1 week later, 1 h after a 10-mg oral dose of selegiline. Three out of eight patients also had a third F-THK5351 scan 9-28 days after the selegiline administration. The primary outcome measure was standardized uptake value (SUV), calculated using tissue radioactivity concentration from 50 to 70 min after F-THK5351 injection, normalizing for body weight and injected radioactivity. The SUV ratio (SUVR) was determined using the cerebellar cortex as the reference region. F-THK5351 competition autoradiography studies in postmortem tissue were conducted using 150 and 500 nM selegiline.

RESULTS

At baseline, F-THK5351 SUVs were highest in the basal ganglia (0.64 ± 0.11) and thalamus (0.62 ± 0.14). In the post-selegiline scans, the regional SUVs were reduced on average by 36.7% to 51.8%, with the greatest reduction noted in the thalamus (51.8%) and basal ganglia (51.4%). MAO-B inhibition also reduced F-THK5351 SUVs in the cerebellar cortex (41.6%). The SUVs remained reduced in the three patients imaged at 9-28 days. Tissue autoradiography confirmed the effects of MAO-B inhibition on F-THK5351 uptake.

CONCLUSIONS

These results indicate that the interpretation of F-THK5351 PET images, with respect to tau, is confounded by the high MAO-B availability across the entire brain. In addition, the heterogeneous MAO-B availability across the cortex may limit the interpretation of F-THK5351 scans using reference region methods.

摘要

背景

F-THK5351是一种喹啉衍生的tau成像剂,对双螺旋丝(PHF)具有高亲和力。然而,F-THK5351在被认为PHF浓度可忽略不计的脑区中大量滞留,这引发了对正电子发射断层扫描(PET)信号解读的质疑,特别是考虑到先前描述的喹诺酮衍生物与单胺氧化酶B(MAO-B)之间的相互作用。在此,我们使用PET和放射自显影技术测试了MAO-B抑制对F-THK5351脑摄取的影响。

方法

八名参与者(五名轻度认知障碍、两名阿尔茨海默病和一名进行性核上性麻痹患者)进行了基线F-AZD4694和F-THK5351扫描,以分别量化脑淀粉样蛋白和PHF负荷。1周后,在口服10毫克司来吉兰1小时后进行第二次F-THK5351扫描。八名患者中有三名在司来吉兰给药后9 - 28天还进行了第三次F-THK5351扫描。主要结局指标是标准化摄取值(SUV),使用F-THK5351注射后50至70分钟的组织放射性浓度计算,以体重和注射放射性进行归一化。SUV比值(SUVR)以小脑皮质作为参考区域来确定。使用150和500 nM司来吉兰对死后组织进行F-THK5351竞争放射自显影研究。

结果

基线时,F-THK5351的SUV在基底神经节(0.64±0.11)和丘脑(0.62±0.14)中最高。在司来吉兰扫描后,区域SUV平均降低了36.7%至51.8%,丘脑(51.8%)和基底神经节(51.4%)的降低最为明显。MAO-B抑制也降低了小脑皮质中F-THK5351的SUV(41.6%)。在9 - 28天成像的三名患者中,SUV仍然降低。组织放射自显影证实了MAO-B抑制对F-THK5351摄取的影响。

结论

这些结果表明,就tau而言,F-THK-5351 PET图像的解读因全脑MAO-B的高可用性而受到混淆。此外,皮质中MAO-B可用性的异质性可能会限制使用参考区域方法对F-THK5351扫描的解读。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82c6/5374697/c2aad9723ba8/13195_2017_253_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验